Financing co-led by Elaia, Pfizer Ventures and Bpifrance
Enodia is the third Argobio-founded company to achieve a seed financing in 2025
Paris, France, 08 January 2026. Argobio Studio, the launch platform for Europe's best innovative science, today announced the successful seed financing of Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of protein synthesis. Enodia has secured €20.7 million (US$25 million) in Seed financing, co-led by Elaia, Pfizer Ventures and Bpifrance, as part of the InnoBio investment strategy, with participation from Wallonie Entreprendre, MACSF, Institut Pasteur, InvestSud, Sambrinvest and Mission BioCapital in addition to Argobio.
Enodia Therapeutics was created by Argobio Studio after it identified the pioneering foundational research by a leading researcher from the Pasteur Institute. Enodia's proprietary discovery platform uses machine learning to selectively modulate the SEC61 translocon, where secreted and transmembrane proteins are directed into the secretory pathway at the point of synthesis. This enables intervention upstream of disease, without compromising vital physiological functions, and before damage occurs.
The platform leverages a large chemical space spanning several families of well-characterized inhibitors, together with a tailored library of signal-peptide cell lines. The company integrates machine- learning-driven selectivity, proteomics based secretome analysis and structural validation to guide rational drug ...
